A phase I clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Date: 
12 Nov 2015
Source: 
Blood Journal
Audience: 
Professionals
Type of resource: 
Research

We report the results of a multi-center Phase I dose escalation study of the selective BTK inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. There were 9 dose escalation cohorts ranging from 20mg once daily (OD) to 600mg OD with twice daily (BID) regimens of 240mg and 300mg BID also investigated.